Trofosfamide has been used in trials studying the treatment of Ependymomas, Medulloblastomas, Sarcoma, Soft Tissue, Supratentorial PNETs, and Recurrent Brain Tumors.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Trofosfamide. |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Trofosfamide. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Trofosfamide. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Trofosfamide. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Trofosfamide. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Trofosfamide. |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Trofosfamide. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Trofosfamide. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Trofosfamide. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Trofosfamide. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Trofosfamide. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Trofosfamide. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Trofosfamide. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Trofosfamide. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Trofosfamide. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Trofosfamide. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Trofosfamide. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Trofosfamide. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Trofosfamide. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trofosfamide. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Trofosfamide. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Trofosfamide. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Trofosfamide. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Trofosfamide. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Trofosfamide. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Trofosfamide. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Trofosfamide. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Trofosfamide. |
| Flunisolide | The risk or severity of adverse effects can be increased when Flunisolide is combined with Trofosfamide. |
| Bortezomib | The risk or severity of adverse effects can be increased when Bortezomib is combined with Trofosfamide. |
| Cladribine | Trofosfamide may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Trofosfamide. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Trofosfamide. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Trofosfamide. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Trofosfamide. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Trofosfamide. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Trofosfamide. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with Trofosfamide. |
| Vindesine | The risk or severity of adverse effects can be increased when Vindesine is combined with Trofosfamide. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Trofosfamide. |
| Indomethacin | The risk or severity of adverse effects can be increased when Indomethacin is combined with Trofosfamide. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Trofosfamide. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Vinorelbine is combined with Trofosfamide. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Trofosfamide. |
| Beclomethasone dipropionate | The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Trofosfamide. |
| Sorafenib | The risk or severity of adverse effects can be increased when Sorafenib is combined with Trofosfamide. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Trofosfamide. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Trofosfamide. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Trofosfamide. |
| Betamethasone | The risk or severity of adverse effects can be increased when Betamethasone is combined with Trofosfamide. |
| Teniposide | The risk or severity of adverse effects can be increased when Teniposide is combined with Trofosfamide. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Trofosfamide. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Trofosfamide. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Trofosfamide. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Trofosfamide. |
| Zidovudine | The risk or severity of adverse effects can be increased when Zidovudine is combined with Trofosfamide. |
| Cisplatin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Trofosfamide. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Trofosfamide. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Trofosfamide. |
| Vincristine | The risk or severity of adverse effects can be increased when Vincristine is combined with Trofosfamide. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Trofosfamide. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Trofosfamide. |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Trofosfamide. |
| Methotrexate | The risk or severity of adverse effects can be increased when Methotrexate is combined with Trofosfamide. |
| Carbamazepine | The risk or severity of adverse effects can be increased when Carbamazepine is combined with Trofosfamide. |
| Vinblastine | The risk or severity of adverse effects can be increased when Vinblastine is combined with Trofosfamide. |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Trofosfamide. |
| Fluocinolone acetonide | The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Trofosfamide. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Trofosfamide. |
| Imatinib | The risk or severity of adverse effects can be increased when Imatinib is combined with Trofosfamide. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Triamcinolone is combined with Trofosfamide. |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Trofosfamide. |
| Prednisone | The risk or severity of adverse effects can be increased when Prednisone is combined with Trofosfamide. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Pemetrexed is combined with Trofosfamide. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Trofosfamide. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Trofosfamide. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Daunorubicin is combined with Trofosfamide. |
| Irinotecan | The risk or severity of adverse effects can be increased when Irinotecan is combined with Trofosfamide. |
| Methimazole | The risk or severity of adverse effects can be increased when Methimazole is combined with Trofosfamide. |
| Etoposide | The risk or severity of adverse effects can be increased when Etoposide is combined with Trofosfamide. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Trofosfamide. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Dacarbazine is combined with Trofosfamide. |
| Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Trofosfamide. |
| Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Trofosfamide. |
| Prednisolone | The risk or severity of adverse effects can be increased when Prednisolone is combined with Trofosfamide. |
| Sirolimus | The risk or severity of adverse effects can be increased when Sirolimus is combined with Trofosfamide. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Trofosfamide. |
| Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Trofosfamide. |
| Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Trofosfamide. |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Trofosfamide. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Dactinomycin is combined with Trofosfamide. |
| Cytarabine | The risk or severity of adverse effects can be increased when Cytarabine is combined with Trofosfamide. |
| Azathioprine | The risk or severity of adverse effects can be increased when Azathioprine is combined with Trofosfamide. |
| Doxorubicin | The risk or severity of adverse effects can be increased when Doxorubicin is combined with Trofosfamide. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Trofosfamide. |
| Busulfan | The risk or severity of adverse effects can be increased when Busulfan is combined with Trofosfamide. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Trofosfamide. |
| Topotecan | The risk or severity of adverse effects can be increased when Topotecan is combined with Trofosfamide. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Trofosfamide. |
| Thalidomide | The risk or severity of adverse effects can be increased when Thalidomide is combined with Trofosfamide. |